The Precision Peptide Company Targets Launch of the Peptide Pen, Expanding Its U.S.-Made Product Platform
Highlights The Company introduces expected launch of the Peptide Pen, its second commercial product, marking a significant expansion beyond transdermal patches into precision injection delivery Designed, manufactured, and tested in the United States in a cGMP-certified facility using medical-grade materials Features a 5mL dosing configuration, a first for a combined pen-and-vial peptide device, offering significantly more capacity than the standard 3mL cartridges commonly available Interchangeable cartridge system allows customers to switch between different peptide protocols using a single device, reducing cost and complexity Commercial release targeted for August 2026 Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces the introduction of the Peptide Pen (the "Peptide Pen"), the Company's second commercial product. The launch of the Peptide Pen is expected to represent a significant expansion of the Company's product offering, building on its BPC-157 transdermal patch with a new precision injection delivery system.
